Op- og nedture for Proinvestors biotek-darlings
-
Gubra, Zealand Pharma, Anavex, Genmab, ALK-Abelló, Lundbeck, Novo Nordisk
Helge Larsen gennemgår flere af ProInvestors biotek-darlings. Store dele af bioteksektoren har i en lang periode ikke haft det nemt. I Norge, USA og flere andre dele af verden er aktiekursen gået voldsomt tilbage. Det er dog ikke sort det hele. Gubra må siges at være dagens vinder, hvor kursen får et kæmpe løft efter gode data på amylin og vægttabsprocenten. Zealand Pharma har fået opjusteret kursmålet af JP Morgan, og Anavex forventer at indgive ansøgning til de europæiske lægemiddelmyndigheder.
-
Er Gubras nye fedmedata en homerun....? https://proinvestor.com/boards/123030/
-
Transcript: Q&A med CEO Adam Steensberg, Zealand Pharma d. 14. november 2024
Moderator: Helge Larsen, ProInvestor.com
https://nbg1.your-objectstorage.com/proinvestor-dev/forum/ir/cms/QA-Zealand Pharma 2024-11-14.pdf
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind